AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
4D Molecular Therapeutics Inc (NASDAQ:FDMT)
4.06 USD
-0.020 0.490%Sponsored Reports
Loading...
| Previous Close (in USD) | 4.08 |
|---|---|
| Change | -0.020 0.490% |
| 52 W H/L (in USD) | 36.250/9.440 |
| EBITDA (in USD) | -116.549M |
| PE Ratio | -- |
| Volume | 109649 |
| Diluted Eps TTM | -2.36 |
| Total Assets (in USD) | 339.891M |
|---|---|
| Total Liabilities (in USD) | 32.062M |
| Revenue TTM (in USD) | 20.453M |
| Cash (in USD) | 249.108M |
| Market Cap (in USD) | 1,300.341 M |
| Revenue Per Share TTM | 0.473 |
| Gross Profit TTM (in USD) | -77.124M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
5858 Horton Street, Emeryville, CA, United States, 94608
510 505 2680
Employees: 171
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. John F. Milligan Ph.D. | Exec. Chairman | 1961 |
| 2. | Dr. David H. Kirn M.D. | Co-Founder, CEO & Director | 1962 |
| 3. | Ms. Theresa Janke | Co-Founder & Chief of Staff | 1975 |
| 4. | Mr. August J. Moretti Esq., J.D. | Chief Financial Officer | 1951 |
| 5. | Dr. Fred Kamal Ph.D. | Pres & COO | 1963 |
| 6. | Mike Zanoni | VP of Investor Relations | NA |
| 7. | Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal & HR Officer and Corp. Sec. | 1972 |
| 8. | Dr. Robert S. Fishman | Chief Medical Officer & Therapeutic Area Head of Pulmonology | 1962 |
| 9. | Dr. Raphael Schiffmann M.D. | Sr. VP & Therapeutic Area Head of Cardiology | NA |
| 10. | Dr. Robert Y. Kim M.B.A., M.D. | Sr. VP & Clinical Therapeutic Area Head of Ophthalmology | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.140 0.208% | 67.62 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.510 0.756% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-3.525 0.791% | 445.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.870 0.167% | 520 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -107.494M | -71.317M | -56.693M | -49.306M | -9.551M |
| Minority Interest | - | - | - | - | - |
| Net Income | -101.076M | -68.297M | -56.541M | -52.939M | -9.551M |
| Selling General Administrative | 32.908M | 28.011M | 17.238M | 13.895M | 6.167M |
| Gross Profit | 3.129M | 18.038M | 13.612M | 6.986M | 14.13M |
| Reconciled Depreciation | 3.88M | 3.02M | 1.443M | 1.004M | 0.697M |
| Ebit | -113.912M | -74.353M | -56.664M | -50.764M | -10.399M |
| Ebitda | -110.032M | -71.333M | -55.221M | -39.486M | -9.702M |
| Depreciation And Amortization | 3.88M | 3.02M | 1.443M | 11.278M | 0.697M |
| Operating Income | -110.032M | -71.333M | -56.664M | -50.764M | -10.399M |
| Other Operating Expenses | 113.161M | 89.371M | 70.276M | 52.613M | 24.529M |
| Interest Expense | 6.418M | 3.036M | 0.152M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 2.573M | 0.137M | 0.152M | 1.504M | 0.85M |
| Net Interest Income | 2.573M | 0.137M | 0.152M | 1.504M | 0.85M |
| Income Tax Expense | -6.418M | -3.02M | -0.152M | 3.633M | 0.848M |
| Total Revenue | 3.129M | 18.038M | 13.612M | 6.986M | 14.13M |
| Total Operating Expenses | 113.161M | 89.371M | 70.276M | 52.613M | 24.529M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 2.538M | 0.016M | -0.029M | 1.458M | -0.002M |
| Net Income From Continuing Ops | -107.494M | -71.317M | -56.693M | -49.306M | -9.551M |
| Net Income Applicable To Common Shares | -107.494M | -71.317M | -56.693M | -49.306M | -9.551M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 339.891M | 261.846M | 353.487M | 288.331M | 58.234M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 8.356M | 6.957M | 8.456M | 4.444M | 1.878M |
| Total Liab | 32.062M | 30.509M | 560.483M | 31.944M | 131.204M |
| Total Stockholder Equity | 307.829M | -314.49M | -206.996M | 256.387M | -72.97M |
| Other Current Liab | 12.014M | 8.87M | 7.744M | 8.371M | 5.347M |
| Common Stock | 0.004M | 0.003M | 0.003M | 0.003M | 0.001M |
| Capital Stock | 0.004M | 0.003M | 0.003M | 0.003M | 0.001M |
| Retained Earnings | -415.327M | -314.49M | -206.996M | -135.679M | -79.025M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 1.08M | 0.602M | 0.602M | 0.677M |
| Cash | 249.108M | 218.642M | 315.429M | 276.726M | 49.652M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 18.951M | 15.731M | 16.338M | 16.744M | 12.955M |
| Current Deferred Revenue | 0.273M | 0.884M | 2.599M | 6.586M | 5.864M |
| Net Debt | -234.437M | -202.518M | -298.981M | -276.726M | -49.652M |
| Short Term Debt | 3.149M | 2.655M | 1.231M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 14.671M | 16.124M | 16.448M | - | - |
| Other Stockholder Equity | 723.136M | 1.193M | 0.42M | 392.063M | 6.054M |
| Property Plant Equipment | - | 22.262M | 28.953M | 5.073M | 5.049M |
| Total Current Assets | 296.588M | 220.511M | 315.429M | 282.656M | 52.508M |
| Long Term Investments | 10.954M | 4.908M | 67.652M | - | - |
| Short Term Investments | 39.124M | 161.203M | 94.776M | - | - |
| Net Receivables | - | 0.7M | 0.047M | 1.486M | 0.978M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | -8.503M | - | - |
| Accounts Payable | 3.515M | 3.322M | 4.764M | 1.787M | 1.744M |
| Accumulated Other Comprehensive Income | 0.016M | -1.196M | -0.423M | -288.331M | -2.625M |
| Non Currrent Assets Other | 0.684M | 1.08M | -58.547M | 0.602M | 0.677M |
| Non Current Assets Total | 43.303M | 41.335M | 38.058M | 5.675M | 5.726M |
| Capital Lease Obligations | 14.671M | 16.124M | 16.448M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -5.514M | -163.57M | -1M | -3.203M | -0.414M |
| Total Cashflows From Investing Activities | -17.05M | -172.68M | -1M | -3.203M | -0.414M |
| Total Cash From Financing Activities | 3.085M | 118.089M | 278.983M | -2.195M | 84.577M |
| Net Income | -107.494M | -71.317M | -56.693M | -49.306M | -9.551M |
| Change In Cash | -100.65M | -123.725M | 227.074M | -42.109M | 67.911M |
| Begin Period Cash Flow | 153.001M | 276.726M | 49.652M | 91.761M | 23.85M |
| End Period Cash Flow | 52.351M | 153.001M | 276.726M | 49.652M | 91.761M |
| Total Cash From Operating Activities | -86.685M | -69.134M | -50.909M | -36.711M | -16.252M |
| Depreciation | 3.88M | 3.02M | 1.443M | 1.004M | 0.697M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | -4.536M | -0.591M | 2.926M | 0.175M |
| Sale Purchase Of Stock | -0.468M | 114.729M | 278.983M | - | - |
| Other Cashflows From Financing Activities | 0.355M | 3.793M | 73.325M | -2.27M | 84.472M |
| Capital Expenditures | 11.536M | 9.11M | 1M | 3.203M | 0.414M |
| Change In Working Capital | -1.336M | -15.534M | -0.711M | 0.259M | -8.777M |
| Other Non Cash Items | 1.144M | 0.898M | 0.048M | 5.137M | 0.002M |
| Free Cash Flow | -98.221M | -78.244M | -51.909M | -39.914M | -16.666M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1456227 |
| 2. | SPDR® S&P Biotech ETF | 1 year ago | 1207669 |
| 3. | Janus Henderson Global Life Sciences D | 1 year ago | 1036428 |
| 4. | Janus Henderson Global Life Sciences | 1 year ago | 1036428 |
| 5. | iShares Russell 2000 ETF | 1 year ago | 944012 |
| 6. | Janus Henderson Glb Life Scn I2 USD | 1 year ago | 799422 |
| 7. | Janus Selection Global Life Science AUSD | 1 year ago | 790694 |
| 8. | Polar Capital Healthcare Opports Inc | 1 year ago | 790158 |
| 9. | Polar Capital Biotech S Inc | 1 year ago | 750000 |
| 10. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 553690 |
| 11. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 419400 |
| 12. | Fidelity Small Cap Index | 1 year ago | 407498 |
| 13. | iShares Russell 2000 Value ETF | 1 year ago | 347813 |
| 14. | JPM Thematics Genetic Thrps C2 Acc USD | 1 year ago | 347578 |
| 15. | Fidelity Growth Company Fund | 1 year ago | 315544 |
| 16. | iShares Biotechnology ETF | 1 year ago | 312720 |
| 17. | Candriam Eqs L Biotech C USD Cap | 1 year ago | 269000 |
| 18. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 248786 |
| 19. | BlackRock Health Sciences Opps Inv A | 1 year ago | 237618 |
| 20. | Fidelity Extended Market Index | 1 year ago | 212429 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 1 year ago | 4163211 |
| 2. | Bvf Inc | 1 year ago | 3922413 |
| 3. | BlackRock Inc | 1 year ago | 3464587 |
| 4. | HHG PLC | 1 year ago | 3197444 |
| 5. | Deep Track Capital, LP | 1 year ago | 3034453 |
| 6. | Viking Global Investors LP | 1 year ago | 2934914 |
| 7. | Vanguard Group Inc | 1 year ago | 2339943 |
| 8. | Polar Capital Holdings PLC | 1 year ago | 1798492 |
| 9. | Goldman Sachs Group Inc | 1 year ago | 1632686 |
| 10. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1568784 |
| 11. | State Street Corporation | 1 year ago | 1523990 |
| 12. | Novo A/S | 1 year ago | 1400000 |
| 13. | Redmile Group, LLC | 1 year ago | 1261427 |
| 14. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1 year ago | 1078325 |
| 15. | BRAIDWELL LP | 1 year ago | 1052485 |
| 16. | Casdin Capital, LLC | 1 year ago | 1033811 |
| 17. | Geode Capital Management, LLC | 1 year ago | 778162 |
| 18. | Eventide Asset Management, LLC | 1 year ago | 776114 |
| 19. | Dimensional Fund Advisors, Inc. | 1 year ago | 748992 |
| 20. | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1 year ago | 641000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...